Companion Diagnostics at the Intersection of Personalized Medicine and Healthcare Delivery

Terzic, André

doi:10.2217/bmm.14.99

Cited by 10 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A companion diagnostics (CDx) is a medical device that is used in conjunction with therapeutic drugs to assess the effect and suitability of drugs on the human body (Waldman and Terzic, 2015). The CDx tests are biomarker tests that help in (Jørgensen, 2021).…”

Section: Companion Diagnosticsmentioning

confidence: 99%

Metabolomics of infectious diseases in the era of personalized medicine

Rahman

Schellhorn

2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Infectious diseases continue to be a major cause of morbidity and mortality worldwide. Diseases cause perturbation of the host’s immune system provoking a response that involves genes, proteins and metabolites. While genes are regulated by epigenetic or other host factors, proteins can undergo post-translational modification to enable/modify function. As a result, it is difficult to correlate the disease phenotype based solely on genetic and proteomic information only. Metabolites, however, can provide direct information on the biochemical activity during diseased state. Therefore, metabolites may, potentially, represent a phenotypic signature of a diseased state. Measuring and assessing metabolites in large scale falls under the omics technology known as “metabolomics”. Comprehensive and/or specific metabolic profiling in biological fluids can be used as biomarkers of disease diagnosis. In addition, metabolomics together with genomics can be used to differentiate patients with differential treatment response and development of host targeted therapy instead of pathogen targeted therapy where pathogens are more prone to mutation and lead to antimicrobial resistance. Thus, metabolomics can be used for patient stratification, personalized drug formulation and disease control and management. Currently, several therapeutics and in vitro diagnostics kits have been approved by US Food and Drug Administration (FDA) for personalized treatment and diagnosis of infectious diseases. However, the actual number of therapeutics or diagnostics kits required for tailored treatment is limited as metabolomics and personalized medicine require the involvement of personnel from multidisciplinary fields ranging from technological development, bioscience, bioinformatics, biostatistics, clinicians, and biotechnology companies. Given the significance of metabolomics, in this review, we discussed different aspects of metabolomics particularly potentials of metabolomics as diagnostic biomarkers and use of small molecules for host targeted treatment for infectious diseases, and their scopes and challenges in personalized medicine.

show abstract

Section: Companion Diagnosticsmentioning

confidence: 99%

Metabolomics of infectious diseases in the era of personalized medicine

Rahman

Schellhorn

2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Deciphering disease pathobiology has led to new therapeutic avenues. Case in point, cancer therapies have been upgraded using biomarkers that inform personalized management [35][36][37][38] . Identification of tyrosine kinase inhibitor-responsive epidermal growth factor receptor variants in a subset of non-small cell lung cancer, and over-expression of human epidermal growth factor receptor 2 in breast cancer, offer guidance for molecular trait-refined individualized treatments 39,40 .…”

Section: The Clinical Dimension Targeting Multimorbiditymentioning

confidence: 99%

Longevity leap: mind the healthspan gap

2021

Self Cite

View full text Add to dashboard Cite

Life expectancy has increased by three decades since the mid-twentieth century. Parallel healthspan expansion has however not followed, largely impeded by the pandemic of chronic diseases afflicting a growing older population. The lag in quality of life is a recognized challenge that calls for prioritization of disease-free longevity. Contemporary communal, clinical and research trends aspiring to extend the health horizon are here outlined in the context of an evolving epidemiology. A shared action integrating public and societal endeavors with emerging interventions that target age-related multimorbidity and frailty is needed. A multidimensional buildout of a curative perspective, boosted by modern anti-senescent and regenerative technology with augmented decision making, would require dedicated resources and cost-effective validation to responsibly bridge the healthspan-lifespan gap for a future of equitable global wellbeing.

show abstract

“…Investment in genomic testing is vital to quickly get patients on the best treatment course, but financial and operational barriers remain. The foremost among these is the cost associated with genomic sequencing and the use of companion diagnostic devices, cited by 28% of Definitive Healthcare’s respondents as the biggest challenge for already-established precision medicine schemes [ 51 ]. This challenge is obviously one of the big obstacles which lead to delay in presentation, diagnosis and treatment as seen in many patients from Nepal [ 47 ].…”

Section: Lack Of Fundsmentioning

confidence: 99%

Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve Status Quo

2021

View full text Add to dashboard Cite

Personalized medicine (PM) has revolutionized oncology management in high human development indexed countries. By interrogating both disease and host factors through a variety of tools, oncologists have been able to better target an individual's cancer, leading to improved outcomes. But both the tools used to define these variables, such as next generation sequencing, large immunohistochemical and fluorescence in situ hybridization (FISH) panels, and the weapons employed against each target are extremely expensive. The expenses have to be measured as not only the direct cost to the patient but also the cost to the system to develop and deploy the necessary infrastructure to optimally use them. However, the concepts of predictive, timely prevention and PM have demonstrated improvement in patient's satisfaction and cost effectiveness. In this paper we will summarize the relevant barriers and challenges that limit the implementation of PM in the developing world with an emphasis on the challenges in Nigeria and Nepal.

show abstract

Companion Diagnostics at the Intersection of Personalized Medicine and Healthcare Delivery

Cited by 10 publications

References 14 publications

Metabolomics of infectious diseases in the era of personalized medicine

Metabolomics of infectious diseases in the era of personalized medicine

Longevity leap: mind the healthspan gap

Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve Status Quo

Contact Info

Product

Resources

About